Manikandan Lakshmanan

Institute of Molecular and Cell Biology

Papers

1

Total Citations

64

H-Index

1

About

Dr. Manikandan Lakshmanan is a leading researcher in cancer biology and targeted therapeutics, with a primary focus on protein N-myristoylation and its role in B-cell malignancies. His most impactful work, the 2020 study "Targeting N-myristoylation for therapy of B-cell lymphomas" (64 citations), systematically demonstrated that N-myristoyltransferase (NMT) is a viable therapeutic target in lymphoma. Dr. Lakshmanan’s research has been instrumental in elucidating how the N-terminal lipid modification myristoylation governs membrane targeting and oncogenic signaling in cancer cells, where NMT expression is frequently elevated. By validating NMT inhibition as a strategy to disrupt these pathways, his contributions have opened new avenues for drug development in hematologic cancers. With a growing citation record, his work bridges fundamental cell biology and translational oncology, offering a compelling rationale for targeting lipid modifications in therapy. Dr. Lakshmanan’s research continues to shape the understanding of post-translational regulation in cancer, making him a key figure in the quest for novel, mechanism-based treatments.

Research Focus

Key Achievements

1
H-Index
1
Papers
64
Total Citations
64
Avg Citations/Paper
🏆 Most Cited Paper
Targeting N-myristoylation for therapy of B-cell lymphomas
64 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Institute of Molecular and Cell Biology

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago